Related Experiment Video

Updated: May 11, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

Design of the tocilizumab in giant cell arteritis trial

Sebastian H Unizony1, Bhaskar Dasgupta, Elena Fisheleva

  • 1Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

International Journal of Rheumatology
|May 9, 2013
PubMed

Insights

The GiACTA trial investigates if tocilizumab (TCZ) helps maintain remission in giant cell arteritis (GCA) patients. TCZ, an IL-6 receptor antagonist, may reduce corticosteroid reliance and side effects.

Area of Science:

  • Rheumatology
  • Immunology
  • Clinical Trials

Background:

  • Giant cell arteritis (GCA) is a chronic inflammatory condition affecting large arteries.
  • Corticosteroids are the current standard of care but are associated with significant long-term adverse effects.
  • Interleukin-6 (IL-6) signaling plays a key role in the pathogenesis of GCA.

Purpose of the Study:

  • To evaluate the efficacy of tocilizumab (TCZ) in maintaining disease remission in GCA patients.
  • To compare TCZ plus a 6-month prednisone taper versus placebo plus a 6- or 12-month prednisone taper.
  • To assess the potential of TCZ to minimize long-term corticosteroid-related adverse events.

Main Methods:

  • The GiACTA trial is a multicenter, randomized, double-blind, placebo-controlled study.
  • 250 patients with active GCA were enrolled across approximately 100 centers.
  • Patients received TCZ (162 mg weekly or every other week) or placebo, combined with a 6- or 12-month prednisone taper.

Main Results:

  • The primary efficacy endpoint is sustained remission (SR) at 52 weeks.
  • Hypothesis: TCZ plus a 6-month prednisone course leads to higher SR rates compared to placebo with a 6-month prednisone course alone.
  • Secondary outcomes will assess the impact on corticosteroid-induced adverse effects.

Conclusions:

  • The GiACTA trial will determine if inhibiting IL-6 signaling is beneficial for GCA patients.
  • The study aims to provide evidence for a new therapeutic strategy in GCA management.
  • Results will inform clinical practice regarding the use of TCZ in GCA.

More Related Videos

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...